1. Introduction
===============

Feline calicivirus (FCV), belonging to the family *Caliciviridae* genera *Vesivirus*, is a small non-enveloped virus with a diameter of 35--38 nm. The virus has a single-stranded, positive sense RNA genome approximately 7.7 kb in length and contains three open reading frames (ORFs): ORF1 ([@bib36]), ORF2 ([@bib3]) and ORF3 ([@bib35]).

Although FCV isolates are closely related and constitute one serotype, there are several strains which differ in pathogenicity and antigenicity able to adapt in many heterogeneous conditions ([@bib16]).

In cats, FCV infection is usually inapparent or associated with mild upper respiratory disease and/or signs of oral ulceration. Less commonly some isolates can cause an acute febrile lameness syndrome ([@bib24], [@bib6]) as well as abortion ([@bib7]) and severe pneumonia. Moreover, during the last decade, highly virulent strains of FCV (VSD-FCV: virulent systemic disease-FCV) have emerged that are associated with outbreaks of disease with high mortality (about 50%) ([@bib23], [@bib14], [@bib25], [@bib4]) and a new range of clinical features characterized by high persistent fever, severe edema of face and limbs, pancreatitis or pneumonia ([@bib34]).

FCV is a common pathogen of domestic cats, but has been isolated from several large felids in captivity and in the wild; for this reason it was suggested that all members of the *Felidae* are susceptible and there are no alternative hosts ([@bib30]).

Occasionally some caliciviruses have also been found in dogs. Four apparently distinct types of calicivirus in dogs have been described: calicivirus serologically related to FCV (FCV-like) associated to glossitis or enteric infection ([@bib8], [@bib9], [@bib10], [@bib27], [@bib20]); canine calicivirus (CaCV), isolated from the feces of diarrheal dogs and which differed genetically and antigenically from FCV ([@bib33], [@bib21]); *Norovirus* GIV.2 detected from a puppy with a severe gastroenteritis ([@bib19]); and calicivirus isolated from dogs with genital disease ([@bib5]).

A seroprevalence study ([@bib28]) has been shown that dogs FCV are widespread in the dogs population, as well as in another report ([@bib1]) has been observed an association between the presence of dogs and FCV infection in cats. However, to date, the role of these viruses in the epidemiology of FCV in cats and dogs is uncertain ([@bib30]).

We report the results of a study based on genotypic and phenotypic characterization of a FCV strain isolated from a dog with enteritis and preliminary serological survey performed on a canine and feline population.

2. Materials and methods
========================

2.1. Virologic investigation
----------------------------

One faecal sample collected from a 3-month old dog with clinical signs of gastroenteritis was forwarded to our laboratories for virologic examination. Faecal sample was homogenised (10%, w/v) in Dulbecco\'s Modified minimal essential medium (D-MEM) plus antibiotics (penicillin 5000 IU/ml, streptomycin 2500 μg/ml, amphotericin B 10 μg/ml), filtered and inoculated onto confluent Madin--Darby canine Kidney (MDCK), feline Crandell Kidney (CrFK) and dog adenocarcinoma (A72) cell line. After 3 days of incubation at 37 °C, the inoculated cells were tested for FCV, canine coronavirus (CCoV) and canine adenovirus (CAV) antigens by indirect immunofluorescence (IF) assay using a cat serum positive for FCV vaccinal strain F9, a dog serum positive for CCoV and a dog serum positive for CAV antibodies. Faecal sample was passaged three times considered to be negative for, CCoV and CAV. The supernatant of the faecal homogenate and the inoculated monolayers were also subjected to hemoagglutination test (HA) using a suspension containing 1% pig erythrocytes and 1% foetal calf serum (FCS) in a 96-well V-plate to screen against canine parvovirus type 2 (CPV-2). Results were read after 4 h at +4 °C and expressed as the reciprocal of the highest sample dilution able to produce HA.

Faecal sample was also tested for type A rotavirus antigens by an enzyme-linked immunosorbent assay (ELISA) (Biox Diagnostics, Jemelle, Belgium).

2.2. Molecular identification
-----------------------------

Viral RNA from the original faecal sample and infected cells was extracted using the QIAamp RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer\'s instructions. Template RNAs were eluted in 50 μl of RNase-free water and stored at −70 °C until their use. DNA was extracted from faecal homogenate by boiling for 10 min and chilling on ice, whereas nucleic acid purification from infected cells was achieved using the DNeasy Tissue Kit (Qiagen GmbH, Hilden, Germany), followed by final elution of DNA with 200 μl of AE buffer and storage at −70 °C.

Viral RNA was analysed by reverse transcription (RT)-PCR using the following primer sets:-Cali1--Cali2 ([@bib18]) targeted to a region of the ORF2 gene of FCV.-CaCV1--CaCV2 ([@bib31]) to amplify the complete ORF2 gene of CaCV.-p289--p290 ([@bib15]), a broadly reactive primer pair, targeted to highly conserved motives of the RdRp region of the polymerase complex of *Vesivirus*, *Lagovirus*, *Norovirus* and *Sapovirus* genera.-CCV1, CCV2 and CCV3 ([@bib29]) to amplify a segment of the gene encoding for transmembrane protein M of CCoV.

Viral DNA was analysed by PCR using primers *555*/*For*--*555*/*Rev* ([@bib2]) that amplify a 583 bp fragment of the capsid protein-encoding gene of CPV-2. RT-PCR and PCR assays were performed as previously reported ([@bib15], [@bib31], [@bib2], [@bib29], [@bib18]). The PCR products were analysed on agarose gel electrophoresis, stained with ethidium bromide and visualized using UV light.

2.3. Sequence analysis and phylogeny
------------------------------------

PCR products obtained were purified from agarose gel using the commercial kit Qiaex Gel Extraction (Qiagen GmbH, Hilden, Germany) according to the manufacturer\'s instructions. The DNA was then used as template for direct sequencing (Eurofins MWG Operon, Ebersberg, Germany) using primers p289--p290 ([@bib15]), Cali1--Cali2 ([@bib18]) and specific primers designed according to an overlapping strategy. The sequences were assembled and analysed using the BioEdit software package version 2.1 ([@bib13]) and the NCBI\'s ([http://www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov/)) and EMBL\'s ([http://www.ebi.ac.uk](http://www.ebi.ac.uk/)) analysis tools. Phylogenetic and molecular analyses were conducted using Mega 3 program ([@bib17]). The nucleotide sequence data of ORF1 and ORF2 genes have been deposited in the EMBL/GenBank database under accession nos. [EU980609](EU980609) and [EU980610](EU980610), respectively.

2.4. Phenotypic characterization
--------------------------------

Phenotypic characterization was performed following the method described by [@bib22]. In particular, the growth properties of the novel isolate were analysed by plaque assay, temperature inactivation experiments (for 30 min at 41.8, 46.2 and 52.2 °C) and by generation of single and multiple cycle growth curves \[4,8, 12, 24 h post-infection (p.i.) at multiplicities of infection (MOI) of 10 and 0.02 respectively\]. Characterization was done comparing the growth properties of the isolate with those of the F9 vaccine strain.

2.5. Virus-neutralization (VN) assay
------------------------------------

Eighty-six canine serum samples and 81 feline sera collected during years 2006--2008, were tested for neutralizing antibodies against the new isolate and the FCV-F9 vaccine strain. The neutralization assays were performed as previously described ([@bib26]). Briefly, 50 μl of serial twofold diluted serum and 50 μl of infectious culture medium containing 100 TCID~50~ of the FCV-F9 strain were mixed and incubated for 1 h at 37 °C. One hundred microliters (1 × 10^5^  cell/ml) of CrFK cell suspension was then added to each well. The cultures were then incubated for 3 days at 37 °C, 5% with CO~2~. The assay was performed three times for each serum.

3. Results
==========

Typical FCV cythopatic effect was evident from the first passage on CrFK cell cultures. No growth was observed in cultured cells of canine origin. Results were negative for CPV-2, CCoV, CAV and type A rotavirus antigens. The isolate was identified as FCV by IF test using a cat serum anti-FCV ([Fig. 1](#fig1){ref-type="fig"} ).Fig. 1Indirect immunofluorescence analysis on CRFK cells. The intracytoplasmatic fluorescence was revealed by using a cat polyclonal antiserum raised against FCV-F9 vaccinal strain. Magnification, 400×.

Furthermore, the faecal sample and the infected cells at the passage one and three, were screened for *Caliciviridae* family, FCV, CaCV, CCoV and CPV-2 by conventional RT-PCR or PCR. Results were negative for CCoV, CaCV and CPV-2. Caliciviruses were identified by using primers p289--p290 ([@bib15]), whereas the virus was characterized as FCV by using primers Cali1--Cali2 ([@bib18]) specific for the FCV capsid gene ([Fig. 2](#fig2){ref-type="fig"} ).Fig. 2RT-PCR with 289/290 and Cali1/Cali2 primer sets. Line 1: marker (Promega 1 kb DNA ladder); line 2: PCR product obtained using generic calicivirus primers (289/290) of 287 bp in size; line 3: amplicon obtained by specific FCV (Cali1/Cali2) primer set of 924 bp in size.

Nucleotide analysis of the PCR product (924 bp in length) obtained by using specific primers for FCV (Cali1--Cali2), confirmed that the virus was closely related to FCV. The novel isolate was designated FCV-Te/10/07.

A sequence of 1557-nucleotides (nt) of ORF1 gene, encoding partial proteinase--polymerase region (pro--pol) (corresponding at nt positions 3176--4733 of FCV-F9 vaccinal strain: GenBank accession no. [M86379](M86379)) and 1834-nt of ORF2 gene encoding A--E regions of the VP1 capsid protein (corresponding at nt 5371--7260 of F9 strain), were determined. BLAST and FASTA analyses of the ORF1 sequence, revealed nucleotide identity of Te/10/07 to the FCV-F9 of 78.4%, while identity to CaCV/48 was equal to 52.6%. The highest sequence match was found to the F65 strain (UK/1990) (81% nt identity) isolated from cat with lameness and oral disease ([@bib12]). Alignment of ORF2 sequences showed nucleotide identity of Te/10/07 to FCVs sequence available on GenBank database, ranged from about 71% to 80%, while the identity to the F9 strain was 75%. The phylogenetic tree based on the capsid amino acid sequence confirmed that the novel isolate clustered with the FCV group ([Fig. 3](#fig3){ref-type="fig"} ).Fig. 3Phylogenetic analysis of the capsid amino acid sequence of the Te/10/07. Tree was generated by using the neighbour-joining distance method. For each strain, the country and year of isolation and the GenBank accession number are indicated.

Comparative analysis of the deduced amino acids (aa) sequences of the hypervariable region E (426--520 aa), revealed the highest similarity to strain LS015 (92%) (80% nt identity) (UK, 1985--1988) associated with chronic stomatitis ([@bib12]) and to strain F65 (91.5%) (79% nt identity) ([@bib12]); similarity to FCV-F9 was about 87% (75% nt identity), whereas to the canine strain 213/95 (Italy, 2000) ([@bib27], [@bib20]) was 84% (73% of nucleotide identity).

Investigation on the growth properties showed that the Te/10/07 strain tended to produce larger plaques ([Fig. 4](#fig4){ref-type="fig"} ) than FCV-F9 in CrFK cells. Moreover, consistent with their larger plaque size, we found that the growth kinetic of the novel isolate was faster than F9 strain. As described in [Table 1](#tbl1){ref-type="table"} , during the single-cycle growth kinetic experiment (MOI 10) we observed that the peak yield of FCV-Te/10/07 strain was produced between T1 (4 h p.i.) and T2 (8 h p.i.), while FCV F9 strain peak yield occurred at T3 (12 h p.i.) and T4 (24 h p.i.). In the multiple-cycle growth kinetic (MOI 0.02) we found that the titres of Te/10/07 increased exponentially by 4 h p.i. In contrast the F9 vaccine strain showed an exponential growth by 8--12 h p.i.Fig. 4Plaque assay of Te/10/07 and FCV-F9. After incubation at 37 °C for 48 h in humidified 5% CO~2~, the overlay was removed and CrFK cells were stained with 1% (w/v) Neutral Red solution.Table 1Single- (MOI 10) and multiple-cycle (0.02) growth kinetics of FCV-F9 and Te/10/07.MOI 10MOI 0.024 h (*T*~1~)8 h (*T*~2~)12 h (*T*~3~)24 h (*T*~4~)4 h (*T*~1~)8 h (*T*~2~)12 h (*T*~3~)24 h (*T*~4~)FCV-F91.2 × 10^7^1.6 × 10^7^4 × 10^7^3 × 10^6^1.4 × 10^6^1.2 × 10^7^1.1 × 10^8^2 × 10^7^FCV-Te/10/071 × 10^6^1.1 × 10^8^8 × 10^7^1.2 × 10^7^1.9 × 10^8^2 × 10^7^1 × 10^7^1.2 × 10^7^

In thermal inactivation experiments we observed that the loss of infectivity was similar for both strains analysed following 30 min incubation at 46.2 °C and full inactivation at 52.2 °C (data not shown).

By serological investigation, neutralizing antibodies were present against the strain F9 in 63.9% (55/86) of dog sera with titres from 1:2 to 1:16; whereas antibodies anti-FCV-Te/10/07 were found in only seven sera (8.13%) all of which had concurrent neutralization antibodies to F9. A serum of these showed neutralizing antibodies titres against Te/10/07 higher than F9. However, none of the samples tested resulted positive only for the dog strain ([Table 2](#tbl2){ref-type="table"} ).Table 2Antibody titres determined by VN assay: the number of dog sera with each titre against FCV-F9 and Te/10/07.STRAINSPositives1:2[a](#tbl2fn1){ref-type="table-fn"}1:41:81:161:321:641:1281:256FCV-F9751815--------Te/10/07--124--------[^1]

As reported in [Table 3](#tbl3){ref-type="table"} , the prevalence of FCV-F9-antibodies in cats was 76.54% (62/81). Neutralizing antibodies against Te/10/07 strain were recovered in 50.62% (41/81) of samples tested, and 38 sera were positives for F9 strain too, with similar titres or higher. In three cats antibodies were found only against the dog strain.Table 3Antibody titres determined by VN assay: the number of cat sera with each titre against FCV-F9 and Te/10/07.StrainsPositives1:2[a](#tbl3fn1){ref-type="table-fn"}1:41:81:161:321:641:1281 ≥ 256FCV-F96323511212Te/10/07571410212--[^2]

4. Discussion
=============

The high degree of genomic plasticity that characterizes FCV has contributed to the emergence of several variants ([@bib30]), some of which highly transmissible and associated with severe clinical disease ([@bib6], [@bib11], [@bib23]). A number of studies investigated the properties of FCV infection in cats, in contrast little is known about the occurrence and the epidemiology of this virus in dogs, probably because only a few strains have been isolated in cell culture ([@bib8], [@bib9], [@bib10], [@bib27]).

In the present report, an isolate of calicivirus from a 3-month old puppy (Te/10/07) showing enteritis, submitted to genotypic and phenotypic characterization.

Sequence analysis of ORF1 and ORF2 genes showed that FCV-Te/10/07, is a member of genogroup I ([@bib11], [@bib12], [@bib32]). As previously demonstrated for other FCVs ([@bib22], [@bib30]), our strain not form a distinct group based on geographic origin, host range or clinical signs. Comparison of hypervariable region E to the available sequences revealed no consistent differences among Te/10/07 strain and those associated with the most characteristic disease. By BLAST and FASTA analysis of ORF1 and ORF2 genes, our isolate appeared to be most genetically related to the F65 strain (UK, 1990), that has previously been demonstrated experimentally to induce a febrile lameness syndrome ([@bib6], [@bib12]). This observation allowed us to hypothesize that Te/10/07 does not arose from a recombinant event between two different FCV strains or between a FCV strain and a closely related calicivirus.

Investigation on the *in vitro* growth properties of the Te/10/07 strain revealed that our isolate had rapid growth kinetic compared to F9. As previously hypothesized ([@bib22]) it may represent a marker of increased virulence of FCVs *in vivo*.

In accordance with another study performed in Italy ([@bib28]), the serological investigation showed that FCV-F9 is widely recognized in dog populations with a prevalence of 63.9%. In contrast, the percentage of dogs with antibodies to Te/10/07 was very low (8.13%) and none of the samples tested were positive solely for Te/10/07. Similarly in cats, despite of the high prevalence of antibodies against FCV-F9 vaccine strain, only three samples were positive against the Te/10/07. These results suggest that FCV-Te/10/07 is less related antigenically than other isolates to the commonly used vaccine strain F9.

In conclusion, this study confirms the interspecific circulation of FCVs among dogs and cats. The presence of this novel virus into dog population raises some concerns about the role of FCVs in puppy gastroenteritis. Further investigations are needed to determine if FCV-Te/10/07 may be an important cause of diarrhea in dog and if domestic dogs may represent a potential source of infection for cats.
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